Literature DB >> 20185929

Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.

Marta Kalousová1, Marie Jáchymová, Alexandra Germanová, Ales Antonín Kubena, Vladimír Tesar, Tomás Zima.   

Abstract

BACKGROUND: Advanced glycation end products (AGEs) belong to uremic toxins and some pathological effects of AGEs are linked to RAGE (receptor for AGEs). Their precursors are detoxified by the glyoxalase (GLO) system. The A419C (E111A) polymorphism of the GLO I gene is associated with vascular disease in hemodialysis (HD) patients and some RAGE gene polymorphisms are implicated in various pathological states. AIM: To study the relationship of A419C GLO I and four RAGE polymorphisms (-429T/C, -374T/A, 2184A/G and Gly82Ser) in the prognosis of HD patients.
METHODS: The group studied consisted of 214 chronic HD patients prospectively followed up for 43 months. 100 patients died, 48 due to cardiovascular causes.
RESULTS: The Kaplan-Meier analysis showed a higher mortality rate in patient-mutated homozygotes for RAGE -429CC, RAGE 2184GG and GLO I 419CC. A higher hazard risk was confirmed by the Cox proportional hazards model when wild-type homozygotes were taken as reference: RAGE -429CC 2.28 (95% CI 1.04-4.99), RAGE 2184GG 3.16 (95% CI 1.44-6.93), and GLO I 419CC 1.75 (95% CI 1.08-2.86). Both RAGE polymorphisms were also associated with cardiovascular mortality: RAGE -429CC 3.54 (95% CI 1.37-9.14) and RAGE 2184GG 5.04 (95% CI 1.93-13.11).
CONCLUSION: In summary, our study shows for the first time a link between RAGE and GLO polymorphisms in the prognosis of HD patients. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185929     DOI: 10.1159/000285845

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Relationship between RAGE gene polymorphisms and cardiovascular disease prognosis in the Chinese Han population.

Authors:  Jinxiong Gao; Liehua Deng; Ying Wang; Yanke Shi; Xiaohua Xiao; Xueou Zheng; Hao Ren; Dingli Xu
Journal:  Mol Genet Genomics       Date:  2017-06-28       Impact factor: 3.291

2.  Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer.

Authors:  Matúš Chocholatý; Marie Jáchymová; Marek Schmidt; Klára Havlová; Anna Křepelová; Tomáš Zima; Marko Babjuk; Marta Kalousová
Journal:  Tumour Biol       Date:  2014-11-19

Review 3.  Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.

Authors:  Sandeep K Mallipattu; John C He; Jaime Uribarri
Journal:  Semin Dial       Date:  2012-04-30       Impact factor: 3.455

4.  Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.

Authors:  Elom K Aglago; Casper G Schalkwijk; Heinz Freisling; Veronika Fedirko; David J Hughes; Li Jiao; Christina C Dahm; Anja Olsen; Anne Tjønneland; Verena Katzke; Theron Johnson; Matthias B Schulze; Krasimira Aleksandrova; Giovanna Masala; Sabina Sieri; Vittorio Simeon; Rosario Tumino; Alessandra Macciotta; Bas Bueno-de-Mesquita; Guri Skeie; Inger Torhild Gram; Torkjel Sandanger; Paula Jakszyn; Maria-Jose Sánchez; Pilar Amiano; Sandra M Colorado-Yohar; Aurelio Barricarte Gurrea; Aurora Perez-Cornago; Ana-Lucia Mayén; Elisabete Weiderpass; Marc J Gunter; Alicia K Heath; Mazda Jenab
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

5.  Glyoxalase 1-419C>A variant is associated with oxidative stress: implications in prostate cancer progression.

Authors:  Cinzia Antognelli; Letizia Mezzasoma; Ettore Mearini; Vincenzo Nicola Talesa
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.